Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma - Wikidata - awgldk - TriplyDB

Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma

Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma

http://www.wikidata.org/entity/Q36561655

about

Circulating biomarkers to monitor cancer progression and treatment Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer Response biomarkers: re-envisioning the approach to tailoring drug therapy for cancer Circulating Tumor DNA as Biomarkers for Cancer Detection.The feasibility of using mutation detection in ctDNA to assess tumor dynamics.Droplet digital PCR for detection and quantification of circulating tumor DNA in plasma of head and neck cancer patients.MMP-9 overexpression is associated with intragenic hypermethylation of MMP9 gene in melanoma Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer.Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer.Current and Emerging Applications of Droplet Digital PCR in Oncology.Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma.Plasma Circulating Tumor DNA Levels for the Monitoring of Melanoma Patients: Landscape of Available Technologies and Clinical Applications.Feasibility of monitoring advanced melanoma patients using cell-free DNA from plasma.Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib.Distribution of circulating tumor DNA in lung cancer: analysis of the primary lung and bone marrow along with the pulmonary venous and peripheral blood.Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review.Review of the clinical applications and technological advances of circulating tumor DNA in cancer monitoring.Sensitive droplet digital PCR method for detection of TERT promoter mutations in cell free DNA from patients with metastatic melanoma.Intratumor and Intertumor Heterogeneity in Melanoma.BRAF inhibitors: resistance and the promise of combination treatments for melanoma.PAX3d mRNA over 2.76 copies/µL in the bloodstream predicts cutaneous malignant melanoma relapse.Cell-Free DNA in Oncology: Gearing up for Clinic.Detection of tumor-derived DNA dispersed in the airway improves the diagnostic accuracy of bronchoscopy for lung cancer.Blood collection in cell-stabilizing tubes does not impact germline DNA quality for pediatric patients.'Future-proofing' blood processing for measurement of circulating microRNAs in samples from biobanks and prospective clinical trials.Incorporating Blood-based Liquid Biopsy Information into Cancer Staging: Time for a TNMB System?Liquid biomarkers in melanoma: detection and discovery.A field guide for cancer diagnostics using cell-free DNA: From principles to practice and clinical applications.Quantification of altered tissue turnover in a liquid biopsy: a proposed precision medicine tool to assess chronic inflammation and desmoplasia associated with a pro-cancerous niche and response to immuno-therapeutic anti-tumor modalities.Circulating tumor DNA predicts survival in patients with resected high risk stage II/III melanoma.Clinical significance of BRAFV600E mutation in circulating tumor DNA in Chinese patients with melanoma.Impact of genomics on the surgical management of melanoma.Cutaneous melanoma: From pathogenesis to therapy (Review).Clinical value of early detection of circulating tumour DNA-BRAFV600mut in patients with metastatic melanoma treated with a BRAF inhibitor.Concerning the article by Louveau et al "Clinical value of early detection of circulating tumour DNA BRAFV600mut in patients with metastatic melanoma treated with a BRAF inhibitor".Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients.Prognostic value of various subtypes of extracellular DNA in ovarian cancer patients Circulating tumor DNA as a marker of treatment response in BRAF V600E mutated non-melanoma solid tumors From validity to clinical utility: the influence of circulating tumor DNA on melanoma patient management in a real-world setting MMP-9 as a Candidate Marker of Response to BRAF Inhibitors in Melanoma Patients With Mutation Detected in Circulating-Free DNA

P2860

Q26745985-80432D4F-648F-4B89-B1DA-1AA3943898A2 Q26746010-F8CD92CB-EC72-4B21-965B-08DC8136DBA0 Q28074295-B83FED2C-7521-4A55-927B-3B0BAA99EC22 Q33632125-E53278EF-FE0C-439E-8A71-4E4E5FD8BBB3 Q33697983-16A0F00C-DB16-4F34-95B7-2355D650EE26 Q33814851-0DB0252C-025E-49B4-9ABD-3D9F880FBE66 Q37062481-87FD3B3F-8A33-4F23-90D0-0D2007C2A598 Q37536958-8E40C77C-420C-4B3B-AA38-1569AD515B90 Q37641638-B52CB673-5EE7-4B91-A32B-58D9DD74DA80 Q38374623-F8BB08B1-2A65-4C0E-ADED-4D3B25B054A2 Q38618945-F6A6BD14-3971-4B8A-A99C-8EE734F34725 Q39292740-21544F0F-0A6C-442E-BC18-52698D0822CD Q40091164-3B2C8EBD-47CA-4FCB-9B18-362FD33AF4D2 Q41694346-C6FC92E0-18CD-4507-806D-1B41D9AF9793 Q41708857-D4312672-2375-459E-B91B-6FAFA8C73BEF Q42369277-B1217BC9-ECBE-4A50-BCCD-B1A36FCA7929 Q42687570-6AA6A3F9-26C1-4F8D-817B-5109FD09D757 Q43274590-1460C8BD-DF0F-4C82-B763-4D22A65AE08B Q46742817-1D5E01D4-8E7C-4F27-9479-9D72E573B1B9 Q47104481-3AC27DC8-2F79-4799-9FE2-CE86CBCD1AAA Q47120556-61F9333E-CBA6-4271-896A-D09EC173ECE2 Q47142145-263DA857-0EA8-4F35-880A-D5C50C3DE1A3 Q47157939-3E4F5EA2-F476-406B-B637-96BC11CAF9AF Q47170265-A14D7B9C-8FA5-43DB-BF9C-B8BBFF986CE6 Q47286833-463E27FE-91B7-40EB-B503-471F6B812C63 Q47563363-0DB1FDEF-D5B2-4D2B-9BD4-8499A2F6AE34 Q47726847-838492B9-3B97-455E-B86C-2A78BEF6C574 Q48178985-E87FBA20-94E1-4046-B7E8-D25C929D783F Q48206682-8244155C-AA3C-4C5E-8FE0-C9A70FA62219 Q48522100-F6B655CB-CBB2-4EA2-A530-E3E430E124CC Q49464812-41097ED0-BD6C-4C52-BEC5-95B4B29F7E70 Q50010320-93BA0393-72FF-449F-92EB-714EF102CD58 Q52658584-0E0AFD01-A339-48D7-8602-FF954D6333B5 Q55033775-B21DA78F-09F8-405A-A119-B9AB369FD85A Q55186392-6B28063E-4D2F-4F9C-98DA-19F2F6060E81 Q55536917-586BBF13-2062-4189-B0CF-8AD6F7A9A16C Q58702160-8EF50E84-417A-431D-8CE8-6276FD8E1477 Q58704645-577A029B-8B49-4A3B-9426-D4C7A9F3C3FF Q58757488-5A5211CF-316A-4F60-A5ED-0BA7F36B315E Q58781162-2BDD11E0-5A41-4DEF-AA0F-3BDE9D4207A2

P2860

Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma

http://www.wikidata.org/entity/Q36561655

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Circulating tumor DNA to monit ...... ients with metastatic melanoma

@ast

Circulating tumor DNA to monit ...... ients with metastatic melanoma

@en

type

label

Circulating tumor DNA to monit ...... ients with metastatic melanoma

@ast

Circulating tumor DNA to monit ...... ients with metastatic melanoma

@en

prefLabel

Circulating tumor DNA to monit ...... ients with metastatic melanoma

@ast

Circulating tumor DNA to monit ...... ients with metastatic melanoma

@en

P1433

Q36561655-6CE74958-DC50-4295-B233-AF03EB79D931

P1476

Q36561655-2EF699E9-2ADF-4F38-86C3-5468EBC0479B

P2093

Q36561655-0E2CDD54-C045-4533-BDC6-2A357BFA8DAC

Q36561655-36526AC8-C9E9-49AE-B658-1E27FA08D53A

Q36561655-3ED0326A-AABA-4C54-81E5-012ACD853F20

Q36561655-4DB7192F-614C-433E-BFAC-6C715062C8FF

Q36561655-53271DFA-552C-4FED-A54C-8DAE86164472

Q36561655-75BD2219-CA5C-4EF5-BB96-5686FE75FF03

Q36561655-92EBFF06-4791-4F16-A778-3E3F50DC73F5

Q36561655-C7624291-B274-4A21-BA41-063FD7EB86E1

Q36561655-D4A51572-6CD3-48FC-9E96-60893F88AFA8

Q36561655-F7231BE5-E6DA-40C8-87E1-6F531C02E661

P2860

Q36561655-092FBE3B-36AA-4609-B16D-47F8BAD130BC

Q36561655-12119D72-3A44-4C00-8FA6-20922D17CE26

Q36561655-1A8B16B8-7582-421E-9C23-A5432BF5C478

Q36561655-264208BF-5DDC-4A7A-B2BE-C886961EE1D7

Q36561655-2668DE78-8D9B-4404-814B-9A44C8EAD17D

Q36561655-3551EDC4-0C46-454C-B6B2-ED60A3881E86

Q36561655-37DE892C-5DF7-4ECA-BD45-5B5159DD0E75

Q36561655-3D060661-5990-462A-ABB5-BAB09CB405EC

Q36561655-4F1C0038-0ABA-4CC9-8F00-A53008C2C9F0

Q36561655-59B364FA-3DAF-4320-A073-2561DB598CA9

P304

Q36561655-65E5B5FF-08A3-45B3-8F63-C4358BD4A7C5

P31

Q36561655-1C3F106D-1E07-4521-BC02-30E86C737F6C

P356

Q36561655-FB530D09-CED2-4D96-AB73-E16A38562F68

P407

Q36561655-EDF07C1C-5EE7-45B2-AD33-686AF86B3299

P433

Q36561655-B1C353CE-C119-4AE9-BFFA-2200CD09661B

P478

Q36561655-32052161-868A-436E-AB96-47E1D0F1B42D

P50

Q36561655-57339F73-C300-4BCB-968B-25EB147AA7FD

Q36561655-678539B9-BF73-42BB-ADF1-7462B6C624D1

Q36561655-6A78ED97-790F-495D-B037-7AAD5EF1F10D

Q36561655-6BB98296-21BB-40CF-8874-C8F30DAD8666

Q36561655-701C39D6-7876-478A-BC61-9832E940D15E

Q36561655-76243171-2974-40BE-930A-3E18E8EB3569

Q36561655-7A40C3AB-1E54-4722-93CA-0895E0F649FC

Q36561655-B243D8A1-595B-4B7C-85C6-9C216A0D0FA7

Q36561655-BF86A9F5-4289-4EDC-B6EF-DD67D2B75991

P577

Q36561655-C223F200-DD61-4199-9E5C-998C31765742

P5875

Q36561655-AF5978D4-16C7-402D-A576-8FC2FA4639F3

P698

Q36561655-2CA50EAE-F7F2-45C2-BD03-6CF7E028BC27

P932

Q36561655-CDE3EFC8-B91C-41A6-8722-364050ED721D

P356

ONCOTARGET.5788

P1433

P1476

Circulating tumor DNA to monit ...... ients with metastatic melanoma

@en

P2093

Adam Cooper

http://www.w3.org/2001/XMLSchema#string

Anna L Reid

http://www.w3.org/2001/XMLSchema#string

Chris Lomma

http://www.w3.org/2001/XMLSchema#string

Kelvin Siew

http://www.w3.org/2001/XMLSchema#string

Matteo S Carlino

http://www.w3.org/2001/XMLSchema#string

Michael Millward

http://www.w3.org/2001/XMLSchema#string

Michelle R Pereira

http://www.w3.org/2001/XMLSchema#string

Muhammad A Khattak

http://www.w3.org/2001/XMLSchema#string

Suzanah C Boyd

http://www.w3.org/2001/XMLSchema#string

Varsha Tembe

http://www.w3.org/2001/XMLSchema#string

P2860

A landscape of driver mutations in melanoma

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Improved overall survival in melanoma with combined dabrafenib and trametinib.

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

Mutations of the BRAF gene in human cancer

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials

The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers

P304

42008-42018

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.5788

http://www.w3.org/2001/XMLSchema#string

P407

P433

39

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

Richard A. Scolyer

Georgina V. Long

Tarek M Meniawy

James B Freeman

P577

2015-09-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

282351254

http://www.w3.org/2001/XMLSchema#string

P698

26524482

http://www.w3.org/2001/XMLSchema#string

P932

4747205

http://www.w3.org/2001/XMLSchema#string